申请人:Janssen Pharmaceutica NV
公开号:US20200102303A1
公开(公告)日:2020-04-02
Fused compounds of Formula (I) and Formula (II), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions.
Wherein R
1
, R
2
, R
2a
, R
3
, R
3a
, R
4
, and R
4a
are defined herein.
化合物的结构式(I)和结构式(II),含有它们的药物组合物,制备它们的方法,以及使用它们的方法,包括用于治疗与MGL调节相关的疾病状态、紊乱和病况的方法,例如与疼痛、精神障碍、神经障碍(包括但不限于重性抑郁障碍、治疗抵抗性抑郁症、焦虑性抑郁症、躁郁症)、癌症和眼部疾病相关的方法。
其中R1、R2、R2a、R3、R3a、R4和R4a在此处定义。